Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: An open-label, single-arm, phase 2 study

The Lancet Respiratory Medicine

Volumn 3, Issue 4, 2015, Pages 301-309

  Calabrò, Luana ^a   Morra, Aldo ^b   Fonsatti, Ester ^a   Cutaia, Ornella ^a   Fazio, Carolina ^a   Annesi, Diego ^a   Lenoci, Marica ^a   Amato, Giovanni ^a   Danielli, Riccardo ^a   Altomonte, Maresa ^a   Giannarelli, Diana ^c   Di Giacomo, Anna Maria ^a   Maio, Michele ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b Euganea Medica Diagnostic Centre   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; TICILIMUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CANCER STAGING; CLINICAL ARTICLE; COLITIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; FEVER; FOLLOW UP; GASTRITIS; HISTOPATHOLOGY; HUMAN; LIFE EXPECTANCY; MAINTENANCE DRUG DOSE; MALE; MALIGNANT MESOTHELIOMA; MEDICATION COMPLIANCE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; PERICARDITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; SCLERODERMA; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT RESPONSE; CLINICAL TRIAL; DRUG RESISTANCE; LUNG NEOPLASMS; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84926418972     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00092-2     Document Type: Article

References (26)

1. Robinson BW, Lake RA Advances in malignant mesothelioma. N Engl J Med 2005, 353:1591-1603.
2. Ceresoli G, Gridelli C, Santoro A Multidisciplinary treatment of malignant pleural mesothelioma. Oncologist 2007, 12:850-863.
3. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644.
4. Ceresoli GL, Zucali PA, Gianoncelli L, Lorenzi E, Santoro A Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev 2010, 36:24-32.
5. Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008, 26:1698-1704.
6. Grégoire M What's the place of immunotherapy in malignant mesothelioma treatments?. Cell Adh Migr 2010, 4:153-161.
7. Cornelissen R, Heuvers ME, Maat AP, et al. New roads open up for implementing immunotherapy in mesothelioma. Clin Dev Immunol 2012, 2012:927240.
8. Lebbe C, Weber JS, Maio M, et al. Five-year survival rates for patients (pts) with metastatic melanoma (MM) treated with ipilimumab (ipi) in phase II trials. Ann Oncol 2012, 23:9s. (abstr 1116PD).
9. Maio M, Bondarenko I, Robert C, et al. Four-year survival update for metastatic melanoma (MM) patients (pts) treated with ipilimumab (ipi) plus dacarbazine (DTIC) on phase 3 study CA184-024. Ann Oncol 2012, 23:9s. (abstr 1127P).
10. Calabrò L, Danielli R, Sigalotti L, Maio M Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications. Semin Oncol 2010, 37:460-467.
11. Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012, 30:2046-2054.
12. Tarhini AA Tremelimumab: a review of development to date in solid tumors. Immunotherapy 2013, 5:215-229.
13. Ribas A, Kefford R, Marshall MA, et al. Phase III randomized, clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013, 31:616-622.
14. Calabrò L, Ceresoli GL, di Pietro A, et al. CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?. Cancer Immunol Immunother 2015, 64:105-112.
15. Calabrò L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2013, 14:1104-1111.
16. Byrne MJ, Nowak AK Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004, 15:257-260.
17. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immunotherapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15:7412-7420.
18. Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998, 16:145-152.
19. Zucali PA, Simonelli M, Mighetti G, et al. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer 2012, 75:360-367.
20. Di Giacomo AM, Calabrò L, Danielli R, et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10mg/kg within an expanded access programme. Cancer Immunol Immunother 2013, 62:1021-1028.
21. Callahan MK, Wolchok JD, Allison JP Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 2010, 37:473-484.
22. Hillegass JM, Shukla A, Lathrop SA, et al. Inflammation precedes the development of human malignant mesothelioma in a SCID mouse zenograft model. Ann NY Acad Sci 2010, 1203:7-14.
23. Kao SC, Pavlakis N, Harvie R, et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 2010, 16:5805-5813.
24. Meniawy TM, Creaney J, Lake RA, et al. Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma. Br J Cancer 2013, 109:1813-1820.
25. Kao SC-H, van Zandwijk N, Clarke S Comment on 'Neutrophil to lymphocyte ratio in malignant pleural mesothelioma'. Br J Cancer 2014, 111:2376.
26. Abakay O, Tanrikulu AC, Palanci Y, et al. The value of inflammatory parameters in the prognosis of malignant mesothelioma. J Int Med Res 2014, 42:554-565.